Morningstar

Ensoma to Present Preclinical Data and Manufacturing Advancements for In Vivo HSC Engineering Platform to Treat Cancer, Immune Disorders and Genetic Diseases at ASGCT 28th ...

“We look forward to presenting preclinical data at ASGCT that underscore the potential of our in vivo HSC engineering platform to address complex genetic disorders and cancer,” said Robert Peters, ...
Seeking Alpha

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

Company’s Phase 1/2 Clinical Trial of EN-374 in X-linked Chronic Granulomatous Disease is Now Open for Patient Enrollment BOSTON--(BUSINESS WIRE)-- Ensoma, an in vivo hematopoietic stem cell (HSC) ...
Morningstar

Ensoma Unveils Three Programs Leveraging In Vivo Hematopoietic Stem Cell Engineering Platform to Target Genetic, Immune and Oncological Diseases

Lead program advancing to IND filing in H1 2025 for the treatment of X-linked chronic granulomatous disease (X-CGD) will be first in vivo HSC-directed therapy tested in humans Preclinical data to be ...